Intra-articular Corticosteroid versus Hyaluronic injections in the treatment of Patellofemoral Osteoarthritis of the Knee. A comparative double blinded randomized controlled trial.

Efficacy of Single Intra-articular 2% Sodium Hyaluronate versus Corticosteroid Injection in Isolated Patellofemoral Osteoarthritis: A Double-Blind, Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200709009

Enrollment

Registered

2020-07-09

Start date

2020-07-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patellofemoral osteoarthritis patellofemoral osteoarthritis PFOA

Interventions

Receive HA(OSTENILÂ® PLUS sodium hyaluronate 2 % (40 milligrams (mg) / 2.0 mililitres (ml) + Manitol 10mg) intra-articular injection. ,Receive Corticosteroid (Triamcenolone acetonide 40mg/1ml 1ml pl

Active Comparator Drug,Active Comparator Drug

Hyaluronic acid injection,Corticosteroid injection

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patient diagnosed with Isolated Patellofemoral osteoarthritis (Diagnostic criteria: Patient having anterior knee pain while getting up and walking upstairs, physical examination shows tenderness at the patellofemoral joint line, patellar grinding test positive. And Knee Lateral or patella skyline X-RAY/MRI consists of OA change of the Patellofemoral joint. 2. Persistent anterior knee pain with VAS more than 30/100mm despite the conservative treatment for 3 months. 3. Age 35-80 years. 4. Understandable, Co-operate with treatment and follow-up protocol.

Exclusion criteria

Exclusion criteria: 1. Patients with moderate to severe tibiofemoral osteoarthritis. (defined as having the radiographic osteoarthritic change with Kellegren and Lawrence classification of grade 3 or 4 of the tibiofemoral joint.) 2. Patient with abnormal Knee Alignment and Knee deformities. 3. Patient with Knee and Patella Instability. 4. Patient with inflammatory joint disease eg. RA, Crystal induced arthritis. 5. Patient with Post Traumatic patellofemoral osteoarthritis. 6. Patient receiving HA or Corticosteroid injection or previous knee surgery for the past 6 months. 7. Patient allergic to HA or Corticosteroid.

Design outcomes

Primary

Measure	Time frame
VAS pain 100mm 48hr, 72hr, 1wk, 2wks, 4wks, 12wks, 24wks. asking the patient to fill the form with the Visual Analog Scale 100mm	—

Secondary

Measure	Time frame
Kujala score 48hr, 72hr, 1wk, 2wks, 4wks, 12wks, 24wks. using Thai version Kujala score ,Adverse event. 48hr, 72hr, 1wk, 2wks, 4wks, 12wks, 24wks pain, fever, aleergic reaction, infection,Pain during injection 0hr (during injection) VAS pain 100mm	—

Countries

Thailand

Contacts

Public ContactKorawish mekariya

Thammasart university hospital

beam1kung@gmail.com0639500008

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026